Pyxis Oncology falls after launching equity offering
PYXS•Pyxis Oncology shares fell 4.5% post-market after the company launched an offering of stock, pre-funded warrants and accompanying warrants. It intends to use the net proceeds to advance its lead clinical candidate and for working capital and general purposes.
1. Offering proceeds
Pyxis Oncology launched an offering of stock, pre-funded warrants and accompanying warrants. The company said it intends to use the net proceeds to advance micvotabart pelidotin, an antibody-drug conjugate for solid tumors, and for working capital and general purposes.
2. Share performance
Shares were down 4.5% at $2.77 post-market. The stock closed flat at $2.90 on Tuesday and had risen 152% year to date.
